JFU
9F Inc.
$2.94
-1.34%
$34.6M
No data for this timeframe.
Vol
Market Cap$34.6M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$7.2K
Inst. Activity0 buys / 2 sells
SEC Reports1
Recent Activity
Jun 5, 2026
SEC
9F Inc. announced the closing of an entrustment transaction involving the purchase and transfer of loan receivables for
6-K — Impact 4/10
Inst.
RHUMBLINE ADVISERS — TRIM
402 shares ($1.1K)
Inst.
UBS Group AG — NEAR_EXIT
218 shares ($574.00)
Analyst Ratings
0Strong Buy
0Buy
3Hold
4Sell
1Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $5.7K | TRIM |
| RHUMBLINE ADVISERS | $1.5K | TRIM |
2 institutional holders with $7.2K total value (1,867 shares) as of 2026-Q1. Top holders: MORGAN, RHUMBLINE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 1,465 | $5.7K | 79.1% | TRIM -61.6% |
| 2 | RHUMBLINE ADVISERS | 402 | $1.5K | 20.9% | TRIM -41.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | TRIM | 685 | 402 | -41.3% | $1.1K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 25,593 | 218 | -99.1% | $574.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 6,574 | 25,593 | +289.3% | $32.1K | 2025-Q2 |
| RHUMBLINE ADVISERS | TRIM | 1,021 | 685 | -32.9% | $862.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 3,410 | 1,310 | -61.6% | $1.8K | 2025-Q1 |
| RHUMBLINE ADVISERS | TRIM | 3,769 | 1,021 | -72.9% | $1.4K | 2025-Q1 |
| UBS Group AG | DOUBLED | 708 | 6,071 | +757.5% | $9.2K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 910 | 3,410 | +274.7% | $5.1K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 0% buy across 8 analysts — 0 strong buy, 0 buy, 3 hold, 4 sell, 1 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2020-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Nov 1, 2021 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Oct 1, 2021 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Sep 1, 2021 | 0 | 0 | 3 | 4 | 1 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.